CareDx, Inc. (CDNA)
NASDAQ: CDNA · Real-Time Price · USD
16.98
-0.76 (-4.28%)
Mar 10, 2026, 4:00 PM EDT - Market closed
CareDx Employees
As of December 31, 2025, CareDx had 765 total employees, including 761 full-time and 4 part-time employees. The number of employees increased by 115 or 17.69% compared to the previous year.
Employees
765
Change (1Y)
115
Growth (1Y)
17.69%
Revenue / Employee
$496,477
Profits / Employee
-$27,914
Market Cap
869.65M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 765 | 115 | 17.69% | 761 | 4 |
| Dec 31, 2024 | 650 | 7 | 1.09% | 644 | 6 |
| Dec 31, 2023 | 643 | -95 | -12.87% | 635 | 8 |
| Dec 31, 2022 | 738 | 93 | 14.42% | 727 | 11 |
| Dec 31, 2021 | 645 | 170 | 35.79% | 633 | 12 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Myriad Genetics | 2,700 |
| NeoGenomics | 2,500 |
| OPKO Health | 2,275 |
| Fulgent Genetics | 1,315 |
| GeneDx Holdings | 1,300 |
| GRAIL | 1,000 |
| Twist Bioscience | 979 |
| Castle Biosciences | 883 |
CDNA News
- 5 days ago - CareDx Announces VANTx™, an AI‑Powered Clinical Data & Analytics Platform Built on CareDx's Proprietary, Large-Scale, Longitudinal Solid Organ Transplant Datasets - Business Wire
- 11 days ago - CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 13 days ago - CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer - Business Wire
- 14 days ago - CareDx Announces Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 20 days ago - CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference - Business Wire
- 23 days ago - Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells - Seeking Alpha
- 26 days ago - CareDx, Inc. (CDNA) Discusses AlloHeme Clinical Validation Data Review and Launch Timeline in AML and MDS Post-Cell Therapy Transcript - Seeking Alpha